person · Reporting owner

Le Goff Corinne

Disclosed activity across 4 companies

Tapewire entity: 52220
SEC CIK: 0001840912

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Imunon, Inc.IMNN · Entity 8041	Director · President and CEO	March 17, 2023	March 21, 2023
Longboard Pharmaceuticals, Inc.LBPH · Entity 85536	Director	December 02, 2024	December 02, 2024
Moderna, Inc.MRNA · Entity 2025	Chief Commercial Officer	February 01, 2021	February 02, 2021
Viatris IncVTRS · Entity 3277	Chief Commercial Officer	April 15, 2026	April 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Imunon, Inc.

Report date March 17, 2023 · Filed March 21, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2033-03-17	Direct	320,000	Reported balance After 2023-03-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-17 · Grant · Acquired 90,000 · Balance 320,000 F1: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant.

Longboard Pharmaceuticals, Inc.

Report date December 02, 2024 · Filed December 02, 2024

Security / award	Ownership account	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-03-10	Direct	Reported balance After 2024-12-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-03-10	Direct	Reported balance After 2024-12-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-12-02 · Disposition to issuer · Disposed 13,397 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2032-05-23	Direct	Reported balance After 2024-12-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2033-05-24	Direct	Reported balance After 2024-12-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-12-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.94 · Expires 2034-05-22	Direct	Reported balance After 2024-12-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-12-02 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Moderna, Inc.

Report date February 01, 2021 · Filed February 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $157.48 · Expires 2031-02-01	Direct	58,563	Reported balance After 2021-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-02-01 · Grant · Acquired 58,563 · Balance 58,563 F1: 25% of this option will vest and become exercisable on February 1, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	25,400	Reported balance After 2021-02-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-01 · Grant · Acquired 25,400 · Balance 25,400 F2: 25% of the shares subject to this restricted stock unit award will vest on February 1, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of this option will vest and become exercisable on February 1, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on February 1, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Viatris Inc

Report date April 15, 2026 · Filed April 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	107,135	Ending reported balance After 2026-04-15 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-04-15 · Exercise / conversion · Acquired 39,344 · Balance 122,558 Row 2 · 2026-04-15 · Tax withholding · Disposed 17,450 · Balance 105,108 F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 18, 2024. Row 3 · 2026-04-15 · Exercise / conversion · Acquired 3,644 · Balance 108,752 F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 4 · 2026-04-15 · Tax withholding · Disposed 1,617 · Balance 107,135 F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on April 18, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-04-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-15 · Exercise / conversion · Disposed 39,344 · Balance 0 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 39,344 of the RSUs granted on April 18, 2024 vested on each of April 15, 2025 and April 15, 2026.
Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-04-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-15 · Exercise / conversion · Disposed 3,643.8335 · Balance 0 F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 18, 2024.

F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on April 18, 2024.

F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 39,344 of the RSUs granted on April 18, 2024 vested on each of April 15, 2025 and April 15, 2026.

F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.

F6: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 15, 2026 Filed Apr 16, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionDividend Equivalent Units · Derivative	3,643.8335	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-015206 · form4.xml · derivative · entry 6 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,643.8335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F6 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. Read SEC document
April 15, 2026 Filed Apr 16, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionRestricted Stock Units · Derivative	39,344	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-015206 · form4.xml · derivative · entry 5 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 39,344 of the RSUs granted on April 18, 2024 vested on each of April 15, 2025 and April 15, 2026. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 39,344 of the RSUs granted on April 18, 2024 vested on each of April 15, 2025 and April 15, 2026. Read SEC document
April 15, 2026 Filed Apr 16, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	1,617	$13.86	$22,411.62	Disclosure SEC source: 0001140361-26-015206 · form4.xml · nonDerivative · entry 4 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,135 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on April 18, 2024. Read SEC document
April 15, 2026 Filed Apr 16, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	3,644	$0.00	$0.00	Disclosure SEC source: 0001140361-26-015206 · form4.xml · nonDerivative · entry 3 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document
April 15, 2026 Filed Apr 16, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	17,450	$13.86	$241,857.00	Disclosure SEC source: 0001140361-26-015206 · form4.xml · nonDerivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,108 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 18, 2024. Read SEC document
April 15, 2026 Filed Apr 16, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	39,344	$0.00	$0.00	Disclosure SEC source: 0001140361-26-015206 · form4.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	88,984	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008892 · form4.xml · derivative · entry 7 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,984 Underlying: Common Stock · 88,984 shares Expires not disclosed F7 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 29,662 of the RSUs granted on March 6, 2026 will vest on March 6, 2027 and 29,661 will vest on each of March 6, 2028 and March 6, 2029. F7 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 29,662 of the RSUs granted on March 6, 2026 will vest on March 6, 2027 and 29,661 will vest on each of March 6, 2028 and March 6, 2029. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionDividend Equivalent Units · Derivative	2,192.007	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008892 · form4.xml · derivative · entry 6 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,385 Underlying: Common Stock · 2,192.007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs. F6 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs. F5 · balance_after: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionRestricted Stock Units · Derivative	44,165	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008892 · form4.xml · derivative · entry 5 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,328 Underlying: Common Stock · 44,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 44,165 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 44,164 will vest on each of March 6, 2027 and March 6, 2028. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 44,165 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 44,164 will vest on each of March 6, 2027 and March 6, 2028. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	973	$14.16	$13,777.68	Disclosure SEC source: 0001140361-26-008892 · form4.xml · nonDerivative · entry 4 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,214 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	2,193	$0.00	$0.00	Disclosure SEC source: 0001140361-26-008892 · form4.xml · nonDerivative · entry 3 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	19,588	$14.16	$277,366.08	Disclosure SEC source: 0001140361-26-008892 · form4.xml · nonDerivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,994 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:04 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	44,165	$0.00	$0.00	Disclosure SEC source: 0001140361-26-008892 · form4.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 04, 2026 Filed Mar 6, 2026 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionDividend Equivalent Units · Derivative	3,052.9986	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008119 · form4.xml · derivative · entry 6 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,053 Underlying: Common Stock · 3,052.9986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F6 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F5 · balance_after: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. Read SEC document
March 04, 2026 Filed Mar 6, 2026 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionRestricted Stock Units · Derivative	36,720	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008119 · form4.xml · derivative · entry 5 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,721 Underlying: Common Stock · 36,720 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. 36,721 of the RSUs granted on April 18, 2024 vested on March 4, 2025, 36,720 vested on March 4, 2026 and 36,721 will vest on March 4, 2027. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. 36,721 of the RSUs granted on April 18, 2024 vested on March 4, 2025, 36,720 vested on March 4, 2026 and 36,721 will vest on March 4, 2027. Read SEC document
March 04, 2026 Filed Mar 6, 2026 00:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	1,355	$14.71	$19,932.05	Disclosure SEC source: 0001140361-26-008119 · form4.xml · nonDerivative · entry 4 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,417 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on April 18, 2024. Read SEC document
March 04, 2026 Filed Mar 6, 2026 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	3,053	$0.00	$0.00	Disclosure SEC source: 0001140361-26-008119 · form4.xml · nonDerivative · entry 3 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document
March 04, 2026 Filed Mar 6, 2026 00:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	16,300	$14.71	$239,773.00	Disclosure SEC source: 0001140361-26-008119 · form4.xml · nonDerivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,719 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 18, 2024. Read SEC document
March 04, 2026 Filed Mar 6, 2026 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	36,720	$0.00	$0.00	Disclosure SEC source: 0001140361-26-008119 · form4.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 11, 2025 Filed Sep 12, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	SaleCommon Stock	7,032	$10.25	$72,044.95	Disclosure SEC source: 0001140361-25-034919 · form4.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,299 F1 · security: These shares of common stock were sold pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, that was adopted by the reporting person on June 12, 2025. F2 · price: Represents the weighted average price of the reporting person's disposition of 7,032 shares of common stock in transactions ranging from $10.2289 to $10.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionDividend Equivalent Units · Derivative	1,767.6191	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-054892 · ownership.xml · derivative · entry 6 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,768 Underlying: Common Stock · 1,767.6191 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F6 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F5 · balance_after: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionRestricted Stock Units · Derivative	39,344	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-054892 · ownership.xml · derivative · entry 5 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,344 Underlying: Common Stock · 39,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. 39,344 of the RSUs granted on April 18, 2024 vested on April 15, 2025 and 39,344 will vest on April 15, 2026. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. 39,344 of the RSUs granted on April 18, 2024 vested on April 15, 2025 and 39,344 will vest on April 15, 2026. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	855	$7.48	$6,395.40	Disclosure SEC source: 0000950170-25-054892 · ownership.xml · nonDerivative · entry 4 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,331 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on April 18, 2024. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	1,768	$0.00	$0.00	Disclosure SEC source: 0000950170-25-054892 · ownership.xml · nonDerivative · entry 3 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	19,023	$7.48	$142,292.04	Disclosure SEC source: 0000950170-25-054892 · ownership.xml · nonDerivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,418 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 18, 2024. Read SEC document
April 15, 2025 Filed Apr 16, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	39,344	$0.00	$0.00	Disclosure SEC source: 0000950170-25-054892 · ownership.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2025 Filed Mar 10, 2025 22:00 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	132,493	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-036579 · ownership.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,493 Underlying: Common Stock · 132,493 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 44,165 of the RSUs granted on March 6, 2025 will vest on March 6, 2026 and 44,164 will vest on each of March 6, 2027 and March 6, 2028. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 44,165 of the RSUs granted on March 6, 2025 will vest on March 6, 2026 and 44,164 will vest on each of March 6, 2027 and March 6, 2028. Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionDividend Equivalent Units · Derivative	1,172.8857	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-034013 · ownership.xml · derivative · entry 6 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,344 Underlying: Common Stock · 1,172.8857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6 · derivative.exercise_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F6 · derivative.expiration_date: Represents DEUs that accrued with respect to the RSUs previously granted on April 18, 2024 and vest on the same schedule as the underlying RSUs. F5 · balance_after: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionRestricted Stock Units · Derivative	36,721	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-034013 · ownership.xml · derivative · entry 5 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,441 Underlying: Common Stock · 36,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. 36,721 of the RSUs granted on April 18, 2024 vested on March 4, 2025, 36,720 will vest on March 4, 2026 and 36,721 will vest on March 4, 2027. F4 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. 36,721 of the RSUs granted on April 18, 2024 vested on March 4, 2025, 36,720 will vest on March 4, 2026 and 36,721 will vest on March 4, 2027. Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	521	$9.37	$4,881.77	Disclosure SEC source: 0000950170-25-034013 · ownership.xml · nonDerivative · entry 4 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,097 F3 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on April 18, 2024. Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	1,173	$0.00	$0.00	Disclosure SEC source: 0000950170-25-034013 · ownership.xml · nonDerivative · entry 3 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC	Viatris Inc VTRS · Entity 3277	Tax withholdingCommon Stock	16,276	$9.37	$152,506.12	Disclosure SEC source: 0000950170-25-034013 · ownership.xml · nonDerivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,445 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 18, 2024. Read SEC document
March 04, 2025 Filed Mar 6, 2025 00:00 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	36,721	$0.00	$0.00	Disclosure SEC source: 0000950170-25-034013 · ownership.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 02, 2024 Filed Dec 2, 2024 19:27 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	22,500	Not disclosed Strike: $18.94	Not disclosed	Disclosure SEC source: 0001415889-24-028027 · form4-12032024_121254.xml · derivative · entry 5 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2034-05-22 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document
December 02, 2024 Filed Dec 2, 2024 19:27 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	12,500	Not disclosed Strike: $7.06	Not disclosed	Disclosure SEC source: 0001415889-24-028027 · form4-12032024_121254.xml · derivative · entry 4 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2033-05-24 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document
December 02, 2024 Filed Dec 2, 2024 19:27 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	12,367	Not disclosed Strike: $4.40	Not disclosed	Disclosure SEC source: 0001415889-24-028027 · form4-12032024_121254.xml · derivative · entry 3 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,367 shares Expires 2032-05-23 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document
December 02, 2024 Filed Dec 2, 2024 19:27 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	13,397	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001415889-24-028027 · form4-12032024_121254.xml · derivative · entry 2 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,397 shares Expires 2031-03-10 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document
December 02, 2024 Filed Dec 2, 2024 19:27 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	12,367	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001415889-24-028027 · form4-12032024_121254.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,367 shares Expires 2031-03-10 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document
May 23, 2024 Filed May 24, 2024 16:15 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $18.94	$0.00	Disclosure SEC source: 0000950170-24-064604 · ownership.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Voting common stock · 22,500 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 23, 2024, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document
April 18, 2024 Filed Apr 19, 2024 22:05 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	110,162	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-046145 · ownership.xml · derivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,162 Underlying: Common Stock · 110,162 shares Expires not disclosed F2 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 36,721 of the RSUs granted on April 18, 2024 will vest on March 4, 2025, 36,720 will vest on March 4, 2026 and 36,721 will vest on March 4, 2027. F2 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 36,721 of the RSUs granted on April 18, 2024 will vest on March 4, 2025, 36,720 will vest on March 4, 2026 and 36,721 will vest on March 4, 2027. Read SEC document
April 18, 2024 Filed Apr 19, 2024 22:05 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	78,688	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-046145 · ownership.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,688 Underlying: Common Stock · 78,688 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. (Viatris). The RSUs vest in two equal annual installments beginning on April 15, 2025. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. (Viatris). The RSUs vest in two equal annual installments beginning on April 15, 2025. Read SEC document
May 25, 2023 Filed May 26, 2023 16:11 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $7.06	$0.00	Disclosure SEC source: 0001209191-23-032506 · doc4.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Voting common stock · 12,500 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 25, 2023, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document
March 17, 2023 Filed Mar 21, 2023 20:37 UTC	Imunon, Inc. IMNN · Entity 8041	GrantStock Option (Right to Buy) · Derivative	90,000	$0.00 Strike: $1.32	$0.00	Disclosure SEC source: 0001437749-23-007399 · rdgdoc.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 90,000 shares Expires 2033-03-17 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant. Read SEC document
July 18, 2022 Filed Jul 20, 2022 22:27 UTC	Imunon, Inc. CLSN · Entity 8041	GrantStock Option (Right to Buy) · Derivative	177,000	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0001062993-22-016571 · form4.xml · derivative · entry 2 Le Goff Corinne · CIK 0001840912 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires 2032-07-18 F2 · derivative.exercise_date: Represents grant of stock option which vests with respect to 25% of the shares on July 18, 2023 and the remaining 75% percent in equal quarterly installments thereafter such that the stock option will be fully vested and exercisable on the fourth anniversary of July 18, 2026. Read SEC document
July 18, 2022 Filed Jul 20, 2022 22:27 UTC	Imunon, Inc. CLSN · Entity 8041	GrantCommon Stock	53,000	$0.00	$0.00	Disclosure SEC source: 0001062993-22-016571 · form4.xml · nonDerivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 F1 · shares: Represents grant of restricted stock which vests on July 18, 2023. Read SEC document
May 24, 2022 Filed May 31, 2022 08:27 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	GrantStock Option (Right to Buy) · Derivative	12,367	$0.00 Strike: $4.40	$0.00	Disclosure SEC source: 0001209191-22-032733 · doc4.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Underlying: Voting common stock · 12,367 shares Expires 2032-05-23 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 24, 2022, and in any event, will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document
March 11, 2021 Filed Mar 11, 2021 20:36 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	GrantStock Option (Right to Buy) · Derivative	13,397	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-21-019994 · doc4.xml · derivative · entry 2 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,397 Underlying: Voting Common Stock · 13,397 shares Expires 2031-03-10 F2 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 13 equal monthly installments commencing April 7, 2021. Read SEC document
March 11, 2021 Filed Mar 11, 2021 20:36 UTC	Longboard Pharmaceuticals, Inc. LBPH · Entity 85536	GrantStock Option (Right to Buy) · Derivative	12,367	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-21-019994 · doc4.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Underlying: Voting Common Stock · 12,367 shares Expires 2031-03-10 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 36 equal monthly installments commencing April 7, 2021. Read SEC document
February 01, 2021 Filed Feb 2, 2021 21:35 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	25,400	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-003515 · form4.xml · derivative · entry 2 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Underlying: Common Stock · 25,400 shares Expires not disclosed F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 1, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document
February 01, 2021 Filed Feb 2, 2021 21:35 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	58,563	$0.00 Strike: $157.48	$0.00	Disclosure SEC source: 0001127602-21-003515 · form4.xml · derivative · entry 1 Le Goff Corinne · CIK 0001840912 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,563 Underlying: Common Stock · 58,563 shares Expires 2031-02-01 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 1, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.